India’s Panacea Takes On Pfizer Over Prevnar 13 Patent Claims
This article was originally published in PharmAsia News
Executive Summary
Indian vaccine maker Panacea Biotec is bracing up to challenge Pfizer, with a pre-grant opposition against the U.S. firm’s top-selling vaccine brand Prevnar 13. The case that had been delayed by six years is finally ready for hearings, say experts.